Suppr超能文献

降压和降脂治疗预防心脏病发作试验(ALLHAT)心力衰竭验证研究:诊断与预后

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

作者信息

Einhorn Paula T, Davis Barry R, Massie Barry M, Cushman William C, Piller Linda B, Simpson Lara M, Levy Daniel, Nwachuku Chuke E, Black Henry R

机构信息

National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892-7936, USA.

出版信息

Am Heart J. 2007 Jan;153(1):42-53. doi: 10.1016/j.ahj.2006.10.012.

Abstract

BACKGROUND

ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF). However, questions have been raised regarding the validity of the HF diagnosis.

METHODS

The ALLHAT HF Validation Study was designed to validate and elucidate the significance of HF events in ALLHAT. Records for 2778 HF hospitalizations in 1935 patients were centrally reviewed using several prespecified algorithms (based on ALLHAT and Framingham criteria) and reviewers' global clinical judgment. Percent agreement with diagnoses assigned by ALLHAT site physicians, relative risks across randomized comparisons, incidence rates, and mortality after HF hospitalization were evaluated for first events validated by each of the criteria sets.

RESULTS

Percent agreements with site physician diagnoses were 71%, 80%, and 84% for ALLHAT, Framingham, and reviewers' judgment, respectively. Using these 3 criteria, relative risks (95% CI) for new-onset HF compared with chlorthalidone were, respectively, 1.46 (1.27-1.68), 1.42 (1.25-1.62), and 1.45 (1.28-1.64) for amlodipine; 1.18 (1.02-1.28), 1.13 (0.99-1.30), and 1.15 (1.01-1.32) for lisinopril; and 1.79 (1.51-2.11), 1.71 (1.46-2.00), and 1.80 (1.55-2.10) for doxazosin.

CONCLUSIONS

An independent review of source documentation showed a high degree of agreement with the HF diagnoses assigned by site physicians and confirmed the higher risk of HF associated with first-step therapy using amlodipine, lisinopril, or doxazosin compared with chlorthalidone. Thiazide-type diuretics should be the preferred first-step therapy for prevention of HF in high-risk patients with hypertension.

摘要

背景

ALLHAT是一项针对42418例患者的随机、双盲、活性药物对照的高血压治疗试验,该试验报告称,在预防心力衰竭(HF)新发方面,噻嗪类利尿剂(氯噻酮)优于钙通道阻滞剂(氨氯地平)、血管紧张素转换酶抑制剂(赖诺普利)和α1阻滞剂(多沙唑嗪)。然而,关于HF诊断的有效性已出现一些问题。

方法

ALLHAT HF验证研究旨在验证并阐明ALLHAT中HF事件的意义。使用几种预先指定的算法(基于ALLHAT和弗雷明汉标准)以及评审员的整体临床判断,对1935例患者中2778次HF住院记录进行集中审查。针对每个标准集验证的首次事件,评估与ALLHAT现场医生指定诊断的一致性百分比、随机对照中的相对风险、发病率以及HF住院后的死亡率。

结果

ALLHAT、弗雷明汉和评审员判断与现场医生诊断的一致性百分比分别为71%、80%和84%。使用这3项标准,与氯噻酮相比,氨氯地平新发HF的相对风险(95%CI)分别为1.46(1.27 - 1.68)、1.42(1.25 - 1.62)和1.45(1.28 - 1.64);赖诺普利分别为1.18(1.02 - 1.28)、1.13((0.99 - 1.30)和1.15(1.01 - 1.32);多沙唑嗪分别为1.79(1.51 - 2.11)、1.71(1.46 - 2.00)和1.80(1.55 - 2.10)。

结论

对原始资料的独立审查表明,与现场医生指定的HF诊断高度一致,并证实与氯噻酮相比,使用氨氯地平、赖诺普利或多沙唑嗪进行初始治疗时HF风险更高。噻嗪类利尿剂应作为高危高血压患者预防HF的首选初始治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验